Nanoplastics (specifically polystyrene nanoparticles <100nm) cross the blood-brain barrier not just by passive diffusion, but by artificially clustering cholesterol-rich lipid rafts on brain endothelial cells. This clustering triggers aberrant transcytosis and tight junction degradation. I hypothesize that mild cholesterol depletion using Methyl-beta-cyclodextrin (MβCD) will dismantle these artificially stabilized lipid rafts, preventing nanoplastic entry into the brain and restoring BBB integrity.
Reasoning: Recent studies show that nanoplastics can cross the BBB within 2 hours of ingestion. Nanoparticles interact with cellular membranes based on hydrophobicity, often accumulating in cholesterol-rich domains. Since lipid rafts regulate tight junction proteins (like Claudin-5) and endocytosis pathways, plastic-induced rigidification of these rafts perfectly explains both the breach of the BBB and the subsequent neuroinflammation. This is grounded in known membrane biophysics but applies it to the novel problem of microplastic toxicity.
Testable Predictions: In vitro: Treating human brain microvascular endothelial cells (hBMVECs) with polystyrene nanoplastics will show increased lipid raft aggregation (quantifiable via fluorescent CTB staining).
Intervention: Pre-treating hBMVECs with low-dose MβCD to gently deplete cholesterol will significantly reduce the intracellular accumulation of fluorescent nanoplastics.
In vivo: In a mouse model, co-administration of nanoplastics with a targeted lipid-raft disrupter will show a measurable decrease in nanoplastic conce





























